Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis

BACKGROUND: Proprotein convertase subtilisin / Kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents. This drug is related to improving the prognosis of patients with cardiovascular disease (CVD). The purpose of this meta-analysis was to systematically analyze the safety and efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Liming, Liu, Ying, Cao, Ziting, Wang, Jun, Huo, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362201/
https://www.ncbi.nlm.nih.gov/pubmed/37484718
http://dx.doi.org/10.18502/ijph.v52i5.12707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362201/
https://www.ncbi.nlm.nih.gov/pubmed/37484718
http://dx.doi.org/10.18502/ijph.v52i5.12707

Ejemplares similares